Accumulation of β-amyloid protein, abnormal aggregation of Tau protein, oxidative stress, and inflammation are involved in the development and progression of Alzheimer’s disease. Antroquinonol can potentially increaseβ-amyloid clearance and decrease Tau aggregation via the interference with the Ras-PI3K-Akt-mTOR pathway. As to conquer the oxidative stress and inflammation involved in the development and progression of Alzheimer’s disease, Antroquinonol can provide beneficial effects through increasing the level of Nrf2 and inhibit nitric oxide production via induction of AMPK.

Golden Biotechnology was named the winner of the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge and co-operated with Queensland University of Technology, Australia on pre-clinical studies on Alzheimer’s disease.

View research publications on Antroquinonol in Neurodegenerative Disease.

For more clinical trial information please visit